HIGH-TECH RADIATION THERAPY WITH LOCAL DOSE ESCALATION IN CHEMO-RADIATION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. PREDICTORS OF EFFECTIVENESS
##article.numberofdownloads## 47
##article.numberofviews## 638
PDF (Русский)

Keywords

LUNG CANCER
CHEMORADIOTHERAPY
DOSE ESCALATION
SIMULTANEOUS INTEGRATED BOOST
TOXICITY
PREDICTOR FACTORS

How to Cite

Borisova, T., Ardzinba, M., Fedorova, A., Glebovskaya, V., Trofimova, O., Marinov, D., Reutova, Y., Ivanov, S., Alieva, S., Meshcheryakova, N., Breder, V., Laktionov, K., Tkachev, S., Nazarenko, A., & Marinichenko, N. (2018). HIGH-TECH RADIATION THERAPY WITH LOCAL DOSE ESCALATION IN CHEMO-RADIATION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. PREDICTORS OF EFFECTIVENESS. Voprosy Onkologii, 64(6), 774–781. https://doi.org/10.37469/0507-3758-2018-64-6-774-781

Abstract

Relevance: Chemo-radiotherapy of patients with locally advanced forms of NSCLC is the standard of treatment and, with all modern approaches to planning and implementing radiotherapy applied, a median survival of more than 28 months can be achieved. Ways to increase the effectiveness of treatment are now associated with local escalation of radiation dose to the tumor and implementation of the personalized approach concept in chemo-radiotherapy.

Materials and methods: Since 2013 chemo-radiotherapy has been performed for 51 patients with lung cancer of inoperable III stage: IIIA stage-15; IIIB - 36 patients. The treatment was carried out using high-tech radiotherapy (simultaneous integrated boost - SIB-IMRT) and dose escalation up to the zones of hypermetabolism from PET / CT to BED10 = 70-74 Gy for 22-25 fractions. The fractionation regimen for SIB-IMRT was determined by dosimetry: the average dose for lungs was MDL 2) was conducted with a consolidation course after the end of CLT.

Results: With a median follow-up of 42 months 1-, 2-, and 3-year local control rates were 94%, 76%, and 61%, respectively. The maximum registered effect after chemo-radiotherapy in 6 (12%) patients was complete regression of the tumor and, in the remaining cases, partial regression (29-57%) and stabilization (16-31%). Overall 1-, 2- and 3-year survival in the group of patients who received CRT was 80.8% (95% CI, 69.7 - 93.7); 64.6% (95% CI, 50.4 - 82.9); 54.2% (95% CI, 38.3 - 76.9), respectively. Recurrence-free 1-, 2- and 3-year survival: 77.3% (95% CI, 56.7 - 90.2); 48.7% (95% CI, 32.3 - 70.1); 29.2 (95% CI, 18.7 - 43.2), respectively. In 2 patients (5%), isolated local relapse (ILI) was noted at the time of 9 months and 13 months. In the remaining cases there were a simultaneous combination of all types of progression - 17 patients (39%) and distant progression (24 patients (56%)). The third degree pulmonary toxicity was noted in 7 (14%). third degree radial esophagitis was observed in 4 (7%) patients. Single-factor analysis revealed the significant effect on the prognosis of an isolated local recurrence and a near-certain effect on the outcome of treatment of the level of SUVmax in the tumor.

Conclusion: With modern high-tech approaches to the planning and implementation of radiotherapy a personalized local escalation of the irradiation dose is possible, taking into account the predictor effect of SUVmax in the tumor.

https://doi.org/10.37469/0507-3758-2018-64-6-774-781
##article.numberofdownloads## 47
##article.numberofviews## 638
PDF (Русский)

References

Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразования в России и странах СНГ в 2012 г. - Москва, 2014. - 226 с.

Aerts H.J., van Baardwijk A.A., Petit S.F. et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18) fluorodeoxyglucose-PET-CT scan. // Radiother Oncol. - 2009. - Vol. 91. - P. 386-392.

Aupérin A., Le Péchoux C., Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer // J. Clin. Oncol. - 2010. -Vol. 28. - № 13. - P. 2181-2190.

Ball D., Mitchell A., Giroux D., Rami-Porta R. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. // Thorac. Oncol. - 2013. - Vol. 8. - № 3. - P. 315321.

Bradley J.D., Paulus R., Komaki R. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study // Lancet Oncol. - 2015. - № 16. - P. 187-199.

Chen C.P Implication of delayed initiation of radiotherapy accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer // Thorac. Oncol. - 2011. - Vol. 6. - № 11. - P. 1857-1864.

Dess R.T., Sun Y., Matuszak M.M. et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer // J. Clin. Oncol. - 2017. - Vol. 35. - № 13. - P. 1395-1402.

Machtay M., Bae K., Movsas B. et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group // Int. J. Radiat. Oncol. Biol. Phys. - 2012. - Vol. 82. - № 1. - P. 425-434.

Moller D.S., Khalil A.A., Knap M.M. et al. A planning study of radiotherapy dose escalation of PET-active tumor volumes in non-small cell lung cancer patients // Acta. Oncol. - 2011. - № 50. - P. 883-888.

Paesmans M., Garcia C., Wong C.Y et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data // Eur. Respir. J. - 2015. - Vol. 46. - № 6. - P. 1751-1761.

Peeters S.T., Dooms C., Van Baardwijk A. et al. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: how to use E(B)US-NA information in addition to PET-CT for delineation? // Radiother Oncol. - 2016. - Vol. 120. - № 2. - P 273-278.

Stewart L.A., Pignon J.P Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Nonsmall Cell Lung Cancer Collaborative Group // BMJ. - 1995. - Vol. 311. - № 7010. - P. 899-909.

Torre L.A., Bray F., Siegel R.L. et al. Global cancer statistics, 2012 // CA Cancer J. Clin. - 2015. - Vol. 65. - № 2. - P. 87-108.

Turner L.M., Howard J.A., Dehghanpour P et al. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies // Med. Dosim. - 2011. - № 36. - P. 383-388.

Ung YC., Gu C., Cline K. et al. An Ontario Clinical Oncology (OCOG) Randomized Trial (PET START) of FDG PET/CT in Stage 3 Non-small Cell Lung Cancer (NSCLC): Impact of PET on Survival // Int. J. Radiat. Oncol. Biol. Phys. - 2011. - Vol. 81. - № 2. - P 137.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018